$2.72
1.81% yesterday
Nasdaq, Nov 15, 10:12 pm CET
ISIN
US00847G7051
Symbol
AGEN
Sector
Industry

Agenus Inc. Stock price

$2.72
-1.94 41.63% 1M
-8.06 74.77% 6M
-13.84 83.57% YTD
-12.03 81.56% 1Y
-68.92 96.20% 3Y
-70.29 96.27% 5Y
-55.57 95.33% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.05 1.81%
ISIN
US00847G7051
Symbol
AGEN
Sector
Industry

Key metrics

Market capitalization $63.81m
Enterprise Value $460.16m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.87
P/S ratio (TTM) P/S ratio 0.40
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 59.00%
Revenue (TTM) Revenue $160.43m
EBIT (operating result TTM) EBIT $-100.80m
Free Cash Flow (TTM) Free Cash Flow $-170.79m
Cash position $44.78m
EPS (TTM) EPS $-11.00
P/E forward negative
P/S forward 0.48
EV/Sales forward 3.67
Short interest 13.09%
Show more

Is Agenus Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Agenus Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Agenus Inc. forecast:

1x Buy
20%
4x Hold
80%

Analyst Opinions

5 Analysts have issued a Agenus Inc. forecast:

Buy
20%
Hold
80%

Financial data from Agenus Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
160 160
59% 59%
100%
- Direct Costs 16 16
24% 24%
10%
145 145
80% 80%
90%
- Selling and Administrative Expenses 42 42
33% 33%
26%
- Research and Development Expense 188 188
15% 15%
117%
-86 -86
58% 58%
-53%
- Depreciation and Amortization 15 15
49% 49%
10%
EBIT (Operating Income) EBIT -101 -101
53% 53%
-63%
Net Profit -228 -228
16% 16%
-142%

In millions USD.

Don't miss a Thing! We will send you all news about Agenus Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Agenus Inc. Stock News

Neutral
Seeking Alpha
3 days ago
Agenus Inc. (NASDAQ:AGEN ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Alexa Buffa - Corporate Communications Garo Armen - Chairman and CEO Steven O'Day - CMO Robin Taylor - CCO Christine Klaskin - VP of Finance Conference Call Participants Emily Bodnar - H.C. Wainright Madeline Stone - William Blair Operator Good morning and welcome to Agenus' Third Quart...
Neutral
Business Wire
4 days ago
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today provided a corporate update and reported financial results for the third quarter of 2024. “BOT/BAL represents one of the most significant advancements in cancer immunotherapy, showing remarkable results in MSS colorectal cancer where previous treatme...
Neutral
Business Wire
8 days ago
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the presentation of new data on two of its promising investigational immunotherapy candidates, botensilimab and AGEN1721, at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting in Houston, Texas. The data, showcasing...
More Agenus Inc. News

Company Profile

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.

Head office United States
CEO Garo Armen
Employees 389
Founded 1994
Website www.agenusbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today